54 results
8-K
EX-99.1
RNAZ
TransCode Therapeutics Inc
5 Apr 24
TransCode Therapeutics Reports 2023 Results; Provides Business Update
4:51pm
financings in an extremely challenging financial environment.
Refocused our development strategy, prioritizing advancing TTX-MC138 into a Phase 1
424B4
txk8prthcli8gn0 4i
19 Jan 24
Prospectus supplement with pricing info
9:57pm
DEFA14A
v9dmg5g
4 Jan 24
Additional proxy soliciting materials
12:41pm
8-K
EX-10.1
z8neihy cso8
4 Dec 23
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
5:07pm
424B5
ar9gpso8qt530ak
1 Dec 23
Prospectus supplement for primary offering
5:23pm
424B5
95l4 53mcjvfvk1x
26 Oct 23
Prospectus supplement for primary offering
4:29pm
424B4
flahmjtw lngbhkzv8z
27 Sep 23
Prospectus supplement with pricing info
5:26pm